The drug has been approved and launched in India.. But you must understand that, benchmark for quality of NCE is based upon its filing and approval in US market. In India, Lipaglyn contributes merely 100 crores (16-17 million USD) while they spec 300 million USD on development...
Requirement of US market is extreamly stringent (Japan has most stringent regulations). Unless drug does not get approved and launched in USA, it does not come under the roof of global NCE..
There is no such term as global NCE ...
and for that matter Zydus Cadilla holds Global patent for Saroglitazaar !
as far as US FDA approval is concerned ...I agree that it's landmark achievement for any Drug entity. However to get marketing license in Individual countries / regions Drug companies have to go through processes of applying for same at individual Drug Regulatory authorities .
there are many instances how a particular drug is approved in one particular region and not approved in other parts of world .
If drug is good enough companies will foot it to get approved in all possible regions to improve market access .
But this does not anyway diminish NCE status of any drug .
Getting drug approved in US is not easy ....
and so even if Saroglitazzar may have been approved in India alone ...does not diminish its significance as first NCE invented by Indian entity indigenously.
It is proof that NCE can be invented and developed by pharma companies ....and that Indian pharma companies are not just good enough to do copy- cat work ( which in itself also is not an easy task ....)
One way or another India is a powerhouse, me being a Pakistani actually support the Indian stance. They wouldnt have to resort to "stealing" as you so eloquently put it, had the prices been somewhat attainable. A huge population plus a leading world powerhouse, India can toe this line.
The 2.5 lack rupees tag for monthly treatment with sorafenib - a drug which merely prolongs life by 3 months in Kidney cancer / liver cancer ...is just a cruel joke .
2.5 lakh rupees may be life time saving of ordinary people in India and similarly placed developing country ... To be forced to pay such an astounding amount is inhuman even in developed country ...forget about developing countries .
These MNC Pharma companies have been blood sucker fleas ....there is no end to their greed .
If generic drug companies can make profits with even throwaway prices ....that means MNC pharma companies have been too greedy to raise the cost of drug astronomically .
The whole argument about how they need profits to allow them to invest in research is big propaganda .
These MNC Pharma companies are anti humans ....
The story of Indian pharma company is the most illustrious story of ingenuity in service of mankind .
at the height of HIV pandemic millions of AIDS pts were dying in Africa .
Indian pharma companies came forward and with backing of Indian patent Act they churned out incredibly cheaper ARVs which saved millions of lives .
The whole WHO 3 by 5 initiative to make HIV drugs available and accessible across the world was based on the cheaper generic drugs produced by Pharma companies .
The reversal of HIV pandemic course with use of Universal access to ARVs due to cheaper generic drugs is the most eloquent success story in modern medicine besides Small pox eradication and polio elimination .
People who cry hoarse against Indian pharma companies forget this story deliberately ....
Frankly speaking if BAYER had issues with judgement of indian Apex court ...it should have had approached WTO .
after all India has used provisions of TRIPS agreement to issue compulsory license for this particular drug .
If at all WTO should be arbitrator for any such dispute to which India is signatory ...
but to make such a remark ( which is condemned by Germany itself ) is matter of great shame for BAYER !!!
Even their government is not standing with them for such an atrocious remark by a CEO of BAYER .